RxDoctor Payments Data

Floyd Sanders, MD

Internal Medicine · Demorest, GANPI 1689763633

Payments from drug & device makers

$383in general payments, 2019–2025

Across 11 payments — averaging $34.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$143
  • Bayer$109
  • Amarin Pharma, Inc.$73
  • Pfizer$59

What the payments were for

  • Food & beverage$383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen2$143
Bayer1$109
Amarin Pharma, Inc.5$73
Pfizer3$59

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$383 in reported general payments places this provider in the 50th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$216,769
Medicare patients
596
Services billed
4,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$86,021
XareltoRivaroxaban51$64,003
JanuviaSitagliptin Phosphate45$53,569
FarxigaDapagliflozin Propanediol55$45,311
MounjaroTirzepatide41$45,246
JardianceEmpagliflozin39$39,797
OzempicSemaglutide25$36,956
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$36,473
TradjentaLinagliptin21$20,253
JanumetSitagliptin Phos/Metformin Hcl15$14,608
Lantus SolostarInsulin Glargine,hum.Rec.Anlog55$11,271
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,826
SymbicortBudesonide/Formoterol Fumarate15$5,134
Atorvastatin Calcium597$5,025
Rosuvastatin Calcium332$4,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$86,02179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Demorest

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →